UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) March 7, 2008

VION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

     
000-26534
(Commission File Number) 		  13-3671221
(IRS Employer Identification No.)
     
4 Science Park, New Haven, CT
(Address of Principal Executive Offices) 		  06511
(Zip Code)

Registrant’s telephone number, including area code: (203) 498-4210

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 


Item 8.01.

Other Events

On March 7, 2008, Vion Pharmaceuticals, Inc. issued a press release announcing that it had received notification from NASDAQ that Vion had regained compliance with Marketplace Rule 4310(c)(4) since the closing bid price of its common stock. $0.01 par value per share, had traded at $1.00 per share or greater for at least ten consecutive business days. A copy of that press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits

 

Exhibit Number

 

Description

99.1

 

Press release dated March 7, 2008.

 

 

-2-

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VION PHARMACEUTICALS, INC.


Date: March 7, 2008

 

By: 


/s/ Howard B. Johnson

 

 

Name: Howard B. Johnson

 

 

Title: President and Chief Financial Officer

 

 

-3-

 


EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Press release dated March 7, 2008.

 

 

-4-

 

Vion Pharmaceuticals Inc. (MM) (NASDAQ:VIOND)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Vion Pharmaceuticals Inc. (MM).
Vion Pharmaceuticals Inc. (MM) (NASDAQ:VIOND)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Vion Pharmaceuticals Inc. (MM).